Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

Drug Des Devel Ther · 2013 · PMC3593763 · PMID 23494602

Europe PMC DOI

hedged sentence

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

narrowly missed statistical significanceP = 0.072so close (0.05 < p ≤ 0.1)

Despite only eight patients (5.7%) receiving further alemtuzumab in this timeframe, the ARR from year 3 to 5 was still lower with alemtuzumab (0.14 versus 0.28), though this narrowly missed statistical significance ( P = 0.072).

also in 227 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.